HIV cell therapy startup Addimmune heads to Wall Street via blank-check merger
BioPharma Dive,
Addimmune, a biotechnology startup developing a cell therapy for HIV, will go public through a merger with a blank check entity…
Addimmune, a biotechnology startup developing a cell therapy for HIV, will go public through a merger with a blank check entity…
Addimmune, a biotech that is working on a cell therapy for HIV, announced Wednesday that it plans to merge with 10X Capital…
A leading developer of gene and cell therapies is spinning out a new company focused on bringing to market curative gene and…
Addimmune will build upon the success of American Gene Technologies Phase 1 HIV clinical trial, accelerating the clinical…